Topic: combination therapy
Buying oncology specialist Array BioPharma is Pfizer CEO Albert Bourla’s biggest M&A move so far. It represents another big bet by the New York drugmaker on cancer treatments since its $14.3 billion deal for Medivation.
The Tecentriq-chemo approval is the second one for the Roche PD-L1 drug in front-line NSCLC, following an OK for a regimen that also contains Avastin.
With a big head-to-head survival win, Roche is coming after Bayer's standard-of-care Nexavar in front-line liver cancer.
Vertex is in the early stages of its triple combo launch Trikafta, which the company believes can treat up to 90% of cystic fibrosis patients.
It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.
The triple combo era in cystic fibrosis, thanks to Vertex and an FDA green light for its next big blockbuster hope, Trikafta.
Adding Cyramza to Roche’s Tarceva stalled tumor progression by 19.4 months, a seven-month improvement over Tarceva alone.
Talk about making pharma history. Merck's Keytruda has racked up yet another first-of-its-kind approval, this time in a combo with Eisai’s Lenvima.
Amgen’s Kyprolis is finally on track for blockbuster status this year, and new data in tandem with J&J's Darzalex could help boost it even further.
A manufacturing defect led to a 'softening' in response rates with a combo of its NKTR-214 and Opdivo in clinical trials, Nektar said.